Vaunita Cohen Parihar

Vaunita Cohen Parihar

Auto-generated profile, based on publicly available information

Vaunita Cohen Parihar

Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2025 in Cancer Research
Verified
Journal Article
Open access
EGEmily Greene
Emily Greene
NHNatalie K. Horvat
Natalie K. Horvat
DDDeon Bryant Doxie
Deon Bryant Doxie
VPVaunita Cohen Parihar
Vaunita Cohen Parihar
JKJayden Kim
Jayden Kim
GLGregory B. Lesinski
Gregory B. Lesinski
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive tumor type with poor patient outcomes. Most patients present with metastatic disease, which generally has reduced immune infiltration compared with primary tumors. Further work to elucidate the specific cellular features of metastatic PDAC is needed to guide the development of future immunotherapy strategies. In this study, we investigated the hypothesis that PDAC tumors harbor distinct immunologic and stromal features depending on their anatomic site. Multiplex IHC, spatial analysis, and single-cell mass cytometry (CyTOF) uncovered dominant immune and stromal cell populations in tumors derived from 27 primary and 26 liver metastases. Metastatic liver tumors from patients with PDAC contained reduced T-cell infiltration, fibroblast populations, and collagen accumulation than primary lesions, whereas CD68+ cells, often coexpressing CCR2, were more abundant. Spatial analyses revealed distinct immune cell communities in primary and metastatic PDAC, in which cytokeratin 19 (CK19+) cells clustered differentially with αSMA+, CD3+, and CD68+ cells, depending on the tumor site. When comparing tumor-associated regions, the proportion of peritumoral CK19− cells remained consistent, but their composition varied by disease site. CD8+ T cells were significantly less frequent in metastatic tumors, whereas both CD4+ and CD8+ T cells present in primary tumors expressed more transcription factors associated with suppressive properties, including FoxP3 and RORγt. CyTOF revealed that T cells coexpressed multiple inhibitory checkpoint receptors, most notably LAG3 and PD-1. This report reveals that primary and metastatic tumors from patients with PDAC harbor vastly distinct immunologic and stromal features at the protein level. Significance: Protein level analysis reveals distinct immunological and stromal features between primary and metastatic pancreatic tumors, offering a rationale for immunotherapies that target macrophages and increase T-cell abundance in metastatic disease.

11 February 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
LLLiming Lian
Liming Lian
BJBora Jang
Bora Jang
SHSebastian G. Huayamares
Sebastian G. Huayamares
ASAvraham Shakked
Avraham Shakked
KGKara Gentry
Kara Gentry
JDJames E. Dahlman
James E. Dahlman
Granulocyte–macrophage colony-stimulating factor (GM-CSF) deficiency drives autoimmune pulmonary alveolar proteinosis (aPAP), a disease characterized by impaired macrophage-mediated clearance of pulmonary surfactants. Clinical data suggest that inhaled recombinant GM-CSF reduces symptoms in aPAP patients, providing a rationale for mRNA-based GM-CSF replacement therapies. However, these require effective mRNA delivery after nebulization. Here, we report the iterative in vivo design of a lipid nanoparticle, named nebulized lung delivery 2 (NLD2), that efficiently delivers mRNA after nebulization. NLD2 carrying GM-CSF mRNA transfected alveolar macrophages in vivo, leading to interleukin-10 pathway activation and subsequent surfactant lipoprotein clearance. In a preclinical disease model of aPAP, GM-CSF mRNA delivery reduced surfactant protein thickness more than recombinant GM-CSF. These data support continued exploration of nebulized lipid nanoparticle therapies for aPAP.

2 April 2026
Verified
Other
Open access
EGEmily Greene
Emily Greene
NHNatalie K. Horvat
Natalie K. Horvat
DDDeon Bryant Doxie
Deon Bryant Doxie
VPVaunita Cohen Parihar
Vaunita Cohen Parihar
JKJayden Kim
Jayden Kim
GLGregory B. Lesinski
Gregory B. Lesinski
T cells in PDAC tumors are limited and express TFs with suppressive phenotypic properties. A, Representative images of mIHC staining in primary and metastatic tumors. Antibody panel detecting CD8 (red), CD4 (yellow), CK19 (white), and dual CD4+CD8+ cells (orange), with representative cells shown. Scale bar, top, 1,000 μm; bottom, 100 μm. B, Representative single-channel images of CD4+, CD8+, and CD4+CD8+ cell subsets (DAPI, CD4, CD8, and CK19). C and D, Stacked bar graphs show the distribution of CK19+, CD4+, CD8+, CD4+CD8+, and DAPI+CK19−CD4−CD8− (other) cells detected by mIHC in each patient sample as percent of total cells (C) and percent of total phenotyped cells (D). Samples arranged from high to low based on other and CK19+ cells, respectively. E, Bar graphs show the mean ± SD of each T-cell subset (P values indicated). F, Bar graphs show the mean ± SD of TF (T-bet, FoxP3, and RORγt)-positive CD4+ T-cell populations, represented as a percentage of total CD4+ T cells (P values of significant results indicated). G, Representative images of CD4+ T-cell subsets by single-channel DAPI, CD4, CD8, CK19, T-bet, FoxP3, and RORγt. Sample size: primary, n = 24; metastatic, n = 21. E, Statistical analysis was performed using two-way ANOVA; F, statistical analysis was performed using Mann–Whitney tests.

2 April 2026
Verified
Other
Open access
EGEmily Greene
Emily Greene
NHNatalie K. Horvat
Natalie K. Horvat
DDDeon Bryant Doxie
Deon Bryant Doxie
VPVaunita Cohen Parihar
Vaunita Cohen Parihar
JKJayden Kim
Jayden Kim
GLGregory B. Lesinski
Gregory B. Lesinski
Transcription factor levels in CD8+ T cells reveals trends toward suppressive phenotypes

2 April 2026
Verified
Other
Open access
EGEmily Greene
Emily Greene
NHNatalie K. Horvat
Natalie K. Horvat
DDDeon Bryant Doxie
Deon Bryant Doxie
VPVaunita Cohen Parihar
Vaunita Cohen Parihar
JKJayden Kim
Jayden Kim
GLGregory B. Lesinski
Gregory B. Lesinski
Mass cytometry analysis of myeloid and NK cells in primary and metastatic PDAC